Abstract
Angiotensin type 1 receptor blockers are more effective than other antihypertensive agents in slowing the progression of renal disease. Angiotensin II (Ang II) induces production of NAD(P)H oxidase–dependent superoxide in vascular and mesangial cells, but the direct role of Ang II in glomerular superoxide production remains unknown. Here we examined the effect of Ang II on superoxide production both ex vivo and in vivo. Ang II increased superoxide generation in isolated normal glomeruli in a dose-dependent manner, and co-incubation with olmesartan, an angiotensin type 1 receptor blocker, suppressed such increase. Subtotal nephrectomized rats (Nx, n=8) showed impaired renal function, increased glomerular sclerosis, and significantly high superoxide production in glomeruli. These changes were inhibited in olmesartan-treated (n=8), but not hydralazine-treated (n=8) Nx rats. Oxidative stress and nitrosative stress were observed in Nx glomeruli, as evidenced by increased levels of carbonyl protein and nitrotyrosine formation, respectively. These changes were inhibited by 8-week treatment with olmesartan. The apoptosis observed in Nx glomeruli was also suppressed by olmesartan. Superoxide generation in Nx glomeruli was blocked by an NAD(P)H oxidase inhibitor, diphenylene iodinium. The mRNA expression levels of two NAD(P)H oxidase subunits were increased in Nx, and olmesartan significantly reduced the mRNA expression levels. These results indicate that Ang II directly induced superoxide production through activation of NAD(P)H oxidase, and olmesartan would inhibit superoxide production and oxidative stress independent of its blood pressure–lowering effect. These findings support the notion that superoxide plays a primary role in glomerular injury in chronic kidney disease.
Similar content being viewed by others
Article PDF
References
Johnson RJ, Alpers CE, Yoshimura A, et al: Renal injury from angiotensin II–mediated hypertension. Hypertension 1992; 19: 464–474.
Bjorck S, Mulec H, Johnsen SA, Norden G, Aurell M : Renal protective effect of enalapril in diabetic nephropathy. BMJ 1992; 304: 339–343.
Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, The Collaborative Study Group: The effect of angiotensin-converting–enzyme inhibition on diabetic nephropathy. N Engl J Med 1993; 329: 1456–1462.
Anderson S, Rennke HG, Brenner BM : Therapeutic advantage of converting enzyme inhibitors in arresting progressive renal disease associated with systemic hypertension in the rat. J Clin Invest 1986; 77: 1993–2000.
Anderson S, Jung FF, Ingelfinger JR : Renal renin-angiotensin system in diabetes: functional, immunohistochemical, and molecular biological correlations. Am J Physiol 1993; 265: F477–F486.
Kagami S, Border WA, Miller DE, Noble NA : Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-beta expression in rat glomerular mesangial cells. J Clin Invest 1994; 93: 2431–2437.
Anderson PW, Do YS, Hsueh WA : Angiotensin II causes mesangial cell hypertrophy. Hypertension 1993; 21: 29–35.
Griendling KK, Minieri CA, Ollerenshaw JD, Alexander RW : Angiotensin II stimulates NADH and NADPH oxidase activity in cultured vascular smooth muscle cells. Circ Res 1994; 74: 1141–1148.
Cifuentes ME, Rey FE, Carretero OA, Pagano PJ : Upregulation of p67(phox) and gp91(phox) in aortas from angiotensin II–infused mice. Am J Physiol Heart Circ Physiol 2000; 279: H2234–H2240.
Yoshimoto T, Gochou N, Fukai N, Sugiyama T, Shichiri M, Hirata Y : Adrenomedullin inhibits angiotensin II–induced oxidative stress and gene expression in rat endothelial cells. Hypertens Res 2005; 28: 165–172.
Satoh M, Ogita H, Takeshita K, Mukai Y, Kwiatkowski DJ, Liao JK : Requirement of Rac1 in the development of cardiac hypertrophy. Proc Natl Acad Sci U S A 2006; 103: 7432–7437.
Jaimes EA, Galceran JM, Raij L : Angiotensin II induces superoxide anion production by mesangial cells. Kidney Int 1998; 54: 775–784.
Ushio-Fukai M, Alexander RW, Akers M, et al: Reactive oxygen species mediate the activation of Akt/protein kinase B by angiotensin II in vascular smooth muscle cells. J Biol Chem 1999; 274: 22699–22704.
Ushio-Fukai M, Griendling KK, Becker PL, Hilenski L, Halleran S, Alexander RW : Epidermal growth factor receptor transactivation by angiotensin II requires reactive oxygen species in vascular smooth muscle cells. Arterioscler Thromb Vasc Biol 2001; 21: 489–495.
Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB : Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000; 20: 645–651.
Van den Branden C, Ceyssens B, Pauwels M, et al: Effect of mycophenolate mofetil on glomerulosclerosis and renal oxidative stress in rats. Nephron Exp Nephrol 2003; 95: e93–e99.
Greiber S, Munzel T, Kastner S, Muller B, Schollmeyer P, Pavenstadt H : NAD(P)H oxidase activity in cultured human podocytes: effects of adenosine triphosphate. Kidney Int 1998; 53: 654–663.
Koya D, Hayashi K, Kitada M, Kashiwagi A, Kikkawa R, Haneda M : Effects of antioxidants in diabetes-induced oxidative stress in the glomeruli of diabetic rats. J Am Soc Nephrol 2003; 14: S250–S253.
Namikoshi T, Tomita N, Fujimoto S, et al: Isohumulones derived from hops ameliorate renal injury via an anti-oxidative effect in Dahl salt-sensitive rats. Hypertens Res 2007; 30: 175–184.
Satoh M, Fujimoto S, Haruna Y, et al: NAD(P)H oxidase and uncoupled nitric oxide synthase are major sources of glomerular superoxide in rats with experimental diabetic nephropathy. Am J Physiol Renal Physiol 2005; 288: F1144–F1152.
Beckman JS, Koppenol WH : Nitric oxide, superoxide, and peroxynitrite: the good, the bad, and ugly. Am J Physiol 1996; 271: C1424–C1437.
Ishii N, Patel KP, Lane PH, et al: Nitric oxide synthesis and oxidative stress in the renal cortex of rats with diabetes mellitus. J Am Soc Nephrol 2001; 12: 1630–1639.
Hahn S, Kuemmerle NB, Chan W, et al: Glomerulosclerosis in the remnant kidney rat is modulated by dietary alpha-tocopherol. J Am Soc Nephrol 1998; 9: 2089–2095.
Shimizu MH, Coimbra TM, de Araujo M, Menezes LF, Seguro AC : N-Acetylcysteine attenuates the progression of chronic renal failure. Kidney Int 2005; 68: 2208–2217.
Ueno T, Kaname S, Takaichi K, et al: LOX-1, an oxidized low-density lipoprotein receptor, was upregulated in the kidneys of chronic renal failure rats. Hypertens Res 2003; 26: 117–122.
Noda M, Matsuo T, Fukuda R, et al: Effect of candesartan cilexetil (TCV-116) in rats with chronic renal failure. Kidney Int 1999; 56: 898–909.
Yao L, Kobori H, Rahman M, et al: Olmesartan improves endothelin-induced hypertension and oxidative stress in rats. Hypertens Res 2004; 27: 493–500.
Geiszt M, Kopp JB, Varnai P, Leto TL : Identification of renox, an NAD(P)H oxidase in kidney. Proc Natl Acad Sci U S A 2000; 97: 8010–8014.
Li JM, Shah AM : Mechanism of endothelial cell NADPH oxidase activation by angiotensin II. Role of the p47phox subunit. J Biol Chem 2003; 278: 12094–12100.
Bidani AK, Griffin KA : Pathophysiology of hypertensive renal damage: implications for therapy. Hypertension 2004; 44: 595–601.
Takenaka T, Suzuki H, Okada H, et al: Transient receptor potential channels in rat renal microcirculation: actions of angiotensin II. Kidney Int 2002; 62: 558–565.
Ito S, Arima S, Ren YL, Juncos LA, Carretero OA : Endothelium-derived relaxing factor/nitric oxide modulates angiotensin II action in the isolated microperfused rabbit afferent but not efferent arteriole. J Clin Invest 1993; 91: 2012–2019.
Goncalves AR, Fujihara CK, Mattar AL, et al: Renal expression of COX-2, ANG II, and AT1 receptor in remnant kidney: strong renoprotection by therapy with losartan and a nonsteroidal anti-inflammatory. Am J Physiol Renal Physiol 2004; 286: F945–F954.
Haddad IY, Pataki G, Hu P, Galliani C, Beckman JS, Matalon S : Quantitation of nitrotyrosine levels in lung sections of patients and animals with acute lung injury. J Clin Invest 1994; 94: 2407–2413.
Raij L, Baylis C : Glomerular actions of nitric oxide. Kidney Int 1995; 48: 20–32.
Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota A : Apoptosis in glomerular sclerosis. Kidney Int 1996; 49: 103–111.
Zhang W, Khanna P, Chan LL, Campbell G, Ansari NH : Diabetes-induced apoptosis in rat kidney. Biochem Mol Med 1997; 61: 58–62.
Ying WZ, Wang PX, Sanders PW : Induction of apoptosis during development of hypertensive nephrosclerosis. Kidney Int 2000; 58: 2007–2017.
Sugiyama H, Kashihara N, Makino H, Yamasaki Y, Ota Z : Reactive oxygen species induce apoptosis in cultured human mesangial cells. J Am Soc Nephrol 1996; 7: 2357–2363.
Marshall CB, Pippin JW, Krofft RD, Shankland SJ : Puromycin aminonucleoside induces oxidant-dependent DNA damage in podocytes in vitro and in vivo. Kidney Int 2006; 70: 1962–1973.
Macconi D, Bonomelli M, Benigni A, et al: Pathophysiologic implications of reduced podocyte number in a rat model of progressive glomerular injury. Am J Pathol 2006; 168: 42–54.
Kashihara N, Sugiyama H, Makino H : Mechanisms for induction of apoptosis and glomerular disease. Nephrol Dial Transplant 1999; 14 ( Suppl 1): 52–54.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Fujimoto, S., Satoh, M., Horike, H. et al. Olmesartan Ameliorates Progressive Glomerular Injury in Subtotal Nephrectomized Rats through Suppression of Superoxide Production. Hypertens Res 31, 305–313 (2008). https://doi.org/10.1291/hypres.31.305
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1291/hypres.31.305
Keywords
This article is cited by
-
Oxidative stress in chronic kidney disease
Renal Replacement Therapy (2018)
-
Olmesartan reduces inflammatory biomarkers in patients with stable coronary artery disease undergoing percutaneous coronary intervention: results from the OLIVUS trial
Heart and Vessels (2014)
-
Ischemia and Reactive Oxygen Species in Sympathetic Hyperactivity States: A Vicious Cycle that can be Interrupted by Renal Denervation?
Current Hypertension Reports (2013)
-
Different administration schedules of darbepoetin alfa affect oxidized and reduced glutathione levels to a similar extent in 5/6 nephrectomized rats
Clinical and Experimental Nephrology (2013)
-
Effects of olmesartan on arterial stiffness in rats with chronic renal failure
Cardiovascular Diabetology (2012)